Cargando…

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma

Background: Dual-phenotype hepatocellular carcinoma (DPHCC) is associated with high rate of post-operative recurrence and low rate of survival, which may reflect the post-operative persistence of cancer stem cells (CSCs). Here we explored the potential correlation between DPHCC and expression of CSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jie, Qi, Ya-Peng, Ma, Ning, Lu, Fei, Gong, Weng-Feng, Chen, Bin, Ma, Liang, Zhong, Jian-Hong, Xiang, Bang-De, Li, Le-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097958/ https://www.ncbi.nlm.nih.gov/pubmed/32231746 http://dx.doi.org/10.7150/jca.41090

Ejemplares similares

CD133(+)EpCAM(+) Phenotype Possesses More Characteristics of Tumor Initiating Cells in Hepatocellular Carcinoma Huh7 Cells
por: Chen, Yi, et al.
Publicado: (2012)

SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis
por: Park, Hyunjin, et al.
Publicado: (2015)

A Novel Function for KLF4 in Modulating the De-Differentiation of EpCAM(−)/CD133(−) nonStem Cells into EpCAM(+)/CD133(+) Liver Cancer Stem Cells in HCC Cell Line HuH7
por: Firtina Karagonlar, Zeynep, et al.
Publicado: (2020)

A novel nitidine chloride nanoparticle overcomes the stemness of CD133(+)EPCAM(+) Huh7 hepatocellular carcinoma cells for liver cancer therapy
por: Li, Danni, et al.
Publicado: (2022)

Overexpression of p62 is associated with poor prognosis and aggressive phenotypes in osteosarcoma
por: Lu, Yao, et al.
Publicado: (2018)

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma
por: Cai, Xiaobo, et al.
Publicado: (2018)

Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma
por: Park, Youn Young, et al.
Publicado: (2019)

Flow Cytometric Analysis of CD133- and EpCAM-Positive Cells in the Peripheral Blood of Patients with Lung Cancer
por: Skirecki, Tomasz, et al.
Publicado: (2013)

MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer
por: Zhou, Ning, et al.
Publicado: (2015)

Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
por: Hashimoto, Kousuke, et al.
Publicado: (2013)

Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer
por: Pradhan, Tapas, et al.
Publicado: (2019)

Doxorubicin‐induced senescence promotes stemness and tumorigenicity in EpCAM−/CD133− nonstem cell population in hepatocellular carcinoma cell line, HuH‐7
por: Karabicici, Mustafa, et al.
Publicado: (2021)

NDRG3 overexpression is associated with a poor prognosis in patients with hepatocellular carcinoma
por: Jing, Ji-sheng, et al.
Publicado: (2018)

Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB
por: Li, Chun-Yan, et al.
Publicado: (2009)

Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma
por: Hu, Zele, et al.
Publicado: (2020)

The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis
por: Ha, Sang Yun, et al.
Publicado: (2016)

Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma
por: Zhang, Xinyuan, et al.
Publicado: (2017)

Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
por: Chen, Jiewei, et al.
Publicado: (2018)

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma
por: Chen, Yibing, et al.
Publicado: (2018)

Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma
por: Wei, Tao, et al.
Publicado: (2014)

Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus
por: Zhao, Kaikai, et al.
Publicado: (2021)

Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma
por: Wang, Wei, et al.
Publicado: (2023)

SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma
por: Ning, Shanglei, et al.
Publicado: (2018)

Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis
por: Zhang, Jian, et al.
Publicado: (2018)

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients
por: Chen, Yao-Li, et al.
Publicado: (2017)

EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis
por: Ralhan, Ranju, et al.
Publicado: (2010)

Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma
por: Zhu, Zebin, et al.
Publicado: (2018)

Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients
por: Liu, Can, et al.
Publicado: (2017)

FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma
por: Wang, Yan, et al.
Publicado: (2020)

Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jiang, Jie, et al.
Publicado: (2021)

Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma
por: Liu, Yue, et al.
Publicado: (2022)

Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma
por: Caspa Gokulan, Ravindran, et al.
Publicado: (2021)

Overexpression Of Hepatocyte Nuclear Factor-1beta Predicting Poor Prognosis Is Associated With Biliary Phenotype In Patients With Hepatocellular Carcinoma
por: Yu, Dan-Dan, et al.
Publicado: (2015)

A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells
por: Wang, Zihua, et al.
Publicado: (2020)

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
por: Hagiwara, S, et al.
Publicado: (2012)

CD133(+)CXCR4(+ )colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
por: Zhang, Shan-shan, et al.
Publicado: (2012)

CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study
por: HE, AINA, et al.
Publicado: (2012)

High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer
por: Huang, Minjie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_phg07rugnr8uqtqr3fg1ie7g84